Kyverna Therapeutics Announces Regulatory Approval of Phase I/II Clinical Trial for KYV-101 in Germany

KYV 101 is a novel therapy for the treatment of lupus nephritis; a fully human anti-CD19 chimeric antigen receptor T-cell therapy for use in B cell-driven autoimmune diseases.